UniQure moves Huntington's gene therapy to next phase of key trial

UniQure can begin treating patients with the highest dose of its experimental Huntington's disease gene therapy, announcing Thursday that clinical trial monitors found no safety concerns after reviewing data from the first 10 participants who received lower doses.